Saturday, January 20 2018
|We are the Viral Diseases Branch. We protect and sustain the health of the US military
through the conduct of high quality, strategic, and mission relevant infectious diseases research with a
focus on viral diseases. We carry out our mission by developing and testing therapeutic and preventative
drugs and vaccines, supporting global infectious diseases surveillance, completing detailed pathogen and
disease description, and educating and training the next generation of world class scientists and
research support personnel. The Viral Diseases Branch is committed to developing the products which
protect the men and women who protect our Nation.
- Dengue:The most important mosquito borne virus in
the world and #2 infectious diseases threat to the US military. Fifty to 100 million new infections
occur annually in over 120 countries resulting in millions of hospitalizations and tens of thousands
of deaths. Dengue decimated U.S. and allied forces fighting strength in the Pacific theater during
WWII and accounted for 20-30% of undifferentiated fever in Vietnam, Somalia, and Haiti.
Recent outbreaks in Hawaii, Florida, and southern Texas, persistent high-level transmission in
Puerto Rico, and the mosquito vector's presence in large regions of the U.S demonstrate an
emerging domestic risk.
- Adenovirus:The leading cause of Acute Respiratory
Disease (ARD) among basic trainees accounting for thousands of hospitalizations and occasional deaths,
reducing training efficiency and increasing health care and training costs. VDB led the successful
DoD effort to develop and license (2011) vaccines against adenovirus types 4 and 7.
New types (i.e. 14 and 21) emerging as causes of illness in both military (recruits) and
civilian special populations.
- Respiratory Infections and Disease non-Adenovirus:
Respiratory infections cause 25-30% of infectious disease hospitalizations in the military,
second only to injury as a cause of DNBI among deployed forces. Clear strategic threat associated
with pandemic potential of influenza and other respiratory pathogens. Constrictive bronchiolitis
associated with deployment to OIF/OEF, etiology undefined, remains a concern.
- The first influenza vaccine (1948)
- Hepatitis A Vaccine (1995)
- An oral type 4 and 7 Adenovirus Vaccine (1980), next generation vaccine (2011)
- Japanese Encephalitis Virus vaccine (1992), next generation (2009)
- Dengue:Continue work within MIDRP and with industry partners
to develop a safe, efficacious, US FDA licensed dengue vaccine for the Warfighter.
- Adenovirus:Measure impact of current vaccine roll out,
explore development of next generation vaccine with expanded protection profile.
- Respiratory Infections:Support global surveillance of
respiratory viral disease threats, contribute to influenza virus strain selection, identify and characterize
evolving threats ahead of pandemic.
- Pathogen Discovery:Leverage Branch's high throughput
sequencing platforms to identify and characterize pathogens un-typable by routine laboratory methods,
supports multiple Branches in the WRAIR enterprise.
- Operational Research:Special projects embedded with
operational units to define risk and operational impact.
|Viral Diseases Branch
Last Modified Date: 09-September-2016